Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA

Vaccine

Volumn 31, Issue 44, 2013, Pages 5047-5054

  Dayan, Gustavo H ^a   Thakur, Manoj ^a   Boaz, Mark ^a   Johnson, Carol ^b  

^a SANOFI PASTEUR   (France)

^b Clinical Research Consultants   (United States)

Author keywords

Clinical trial; Dengue; Formulation; Immunogenicity; Vaccine

Indexed keywords

DENGUE VACCINE;

ADULT; ARTICLE; CONTROLLED STUDY; DENGUE; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPTIC NEURITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SERODIAGNOSIS; SEROTYPE; SIDE EFFECT; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; VACCINE PRODUCTION;

CLINICAL TRIAL; CYD-TDV; DENGUE; FORMULATION; IMMUNOGENICITY; LOG(10)TISSUE CULTURE INFECTIOUS DOSE 50%; PLAQUE REDUCTION NEUTRALIZATION TEST; PRNT(50); RECOMBINANT LIVE-ATTENUATED TETRAVALENT DENGUE VACCINE; REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION; RT-PCR; TCID(50); VACCINE;

ADULT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; DENGUE; DENGUE VACCINES; DOUBLE-BLIND METHOD; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; NEUTRALIZATION TESTS; UNITED STATES; VACCINES, ATTENUATED; VIREMIA;

EID: 84885428192     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.08.088     Document Type: Article

References (33)

1. Gubler D.J., Clark G.G. Dengue/dengue hemorrhagic fever: the emergence of a global health problem. Emerg Infect Dis 1995, 1:55-57.
2. Gubler D., Dengue urbanization and globalization the unholy trinity of the 21st century. Trop Med Health 2011, 39:3-11.
3. Simmons C.P., Farrar J.J., Nguyen vV., Wills B. Dengue. N Engl J Med 2012, 366:1423-1432.
4. Sabchareon A., Lang J., Chanthavanich P., Yoksan S., Forrat R., Attanath P., et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 2002, 66:264-272.
5. Sabchareon A., Lang J., Chanthavanich P., Yoksan S., Forrat R., Attanath P., et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 2004, 23:99-109.
6. Kanesa-Thasan N., Sun W., Kim-Ahn G., Van Albert S., Putnak J.R., King A., et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 2001, 19:3179-3188.
7. Kitchener S., Nissen M., Nasveld P., Forrat R., Yoksan S., Lang J., et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 2006, 24:1238-1241.
8. Guirakhoo F., Weltzin R., Chambers T.J., Zhang Z.X., Soike K., Ratterree M., et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 2000, 74:5477-5485.
9. Guirakhoo F., Kitchener S., Morrison D., Forrat R., McCarthy K., Nichols R., et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2006, 2:60-67.
10. Capeding R.Z., Luna I.A., Bomasang E., Lupisan S., Lang J., Forrat R., et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine 2011, 29:3863-3872.
11. Guy B., Barrere B., Malinowski C., Saville M., Teyssou R., Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011, 29:7229-7241.
12. Lanata C.F., Andrade T., Gil A.I., Terrones C., Valladolid O., Zambrano B., et al. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru. Vaccine 2012, 30:5935-5941.
13. Morrison D., Legg T.J., Billings C.W., Forrat R., Yoksan S., Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 2010, 201:370-377.
14. Poo J., Galan F., Forrat R., Zambrano B., Lang J., Dayan G.H. Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J 2011, 30:e9-e17.
15. Qiao M., Shaw D., Forrat R., Wartel-Tram A., Lang J. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am J Trop Med Hyg 2011, 85:724-731.
16. Sabchareon A., Wallace D., Sirivichayakul C., Sirivichayakul C., Limkittikul K., Chanthavanich P., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012, 380:1559-1567.
17. Leo Y.S., Wilder-Smith A., Archuleta S., Shek L.P., Chong C.Y., Leong H.N., et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: phase II randomized controlled trial in Singapore. Hum Vaccin Immunother 2012, 8:1259-1271.
18. Guy B., Barban V., Mantel N., Aguirre M., Gulia S., Pontvianne J., et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 2009, 80:302-311.
19. Roehrig J.T., Hombach J., Barrett A.D. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 2008, 21:123-132.
20. Russell P.K., Nisalak A., Sukhavachana P., Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 1967, 99:285-290.
21. Timiryasova T.M., Bonaparte M.I., Luo P., Zedar R., Hu B.T., Hildreth S.W. Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development. Am J Trop Med Hyg 2013, 88:962-970.
22. World Health Organization Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses. WHO/IVB/07.07 2007, WHO, Geneva.
23. World Health Organization Introductory guide for MedDRA 2011, [accessed 09.06.13]. http://www.who.int/medical_devices/innovation/MedDRAintroguide_version14_0_March2011.pdf.
24. Mantel N., Aguirre M., Gulia S., Girerd-Chambaz Y., Colombani S., Moste C., et al. Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines. J Virol Methods 2008, 151:40-46.
25. Dietze R., Garbes P., Dayan G. Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Children and Adolescents in Brazil. XVIII International Congress for Tropical Medicine and Malaria and the XLVIII Congress of the Brazialian Society of Tropical Medicine 2012.
26. Villar L., Rivera-Medina D., Arredondo-Garcia J.L., Zambrano B., Miranda M.C., Rivas E., et al. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16-year-olds: a randomized, controlled, phase II trial in Latin America. Pediatr Infect Dis J 2013, (in press).
27. Makino Y., Tadano M., Saito M., Maneekarn N., Sittisombut N., Sirisanthana V., et al. Studies on serological cross-reaction in sequential flavivirus infections. Microbiol Immunol 1994, 38:951-955.
28. van Panhuis W.G., Gibbons R.V., Endy T.P., Rothman A.L., Srikiatkhachorn A., Nisalak A., et al. Inferring the serotype associated with dengue virus infections on the basis of pre- and postinfection neutralizing antibody titers. J Infect Dis 2010, 202:1002-1010.
29. Zompi S., Montoya M., Pohl M.O., Balmaseda A., Harris E. Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans. PLoS Negl Trop Dis 2012, 6:e1568.
30. Hombach J., Solomon T., Kurane I., Jacobson J., Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 2005, 23:5205-5211.
31. Van G.Y., Klade C.S., Putnak R., Formica A., Krasaesub S., Spruth M., et al. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(R)) induced neutralizing antibody titers. Vaccine 2011, 29:5925-5931.
32. Anderson K.B., Gibbons R.V., Edelman R., Eckels K.H., Putnak R.J., Innis B.L., et al. Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate. J Infect Dis 2011, 204:442-450.
33. Sutter R.W., John T.J., Jain H., Agarkhedkar S., Ramanan P.V., Verma H., et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet 2010, 376:1682-1688.